関連する実験動画
Updated: May 24, 2026

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
甲状腺毒性症候群 甲状腺毒性症候群とは
Jayne A Franklyn1, Kristien Boelaert
1Centre for Diabetes, Endocrinology and Metabolism, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. j.a.franklyn@bham.ac.uk
Lancet (London, England)
|March 8, 2012
まとめ
甲状腺毒性症は,しばしばグレイス病によって引き起こされ,抗甲状腺薬または放射性ヨウ素療法で治療されます. 将来の研究は,より安全で効果的な治療法のための甲状腺機能過剰症の根本的な原因に対処することを目的としています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 内科内科は,内科の内科である.
背景:
- 甲状腺毒性症は,特に女性において,蔓延する内分泌系疾患である.
- グレイヴス病は最も一般的な原因で,次に毒性結節性甲状腺症および甲状腺炎が続きます.
- 現在の治療法は,抗甲状腺薬,放射性ヨウ素療法,甲状腺切除術などです.
研究 の 目的:
- タイロトキシコシスの現在の理解と管理をレビューする.
- 既存の治療法の有効性と限界について議論する.
- タイロトキシコシス研究における将来の方向性を強調する.
主な方法:
- タイロトキシコシスに関する既存の文献のレビュー.
- グラブス病と毒性結節性甲状腺機能過剰症の治療結果の分析.
- 新興治療戦略の議論.
主要な成果:
- 抗甲状腺薬 (チオナミド) は最初の治療法であり,グレイヴス病患者の約3分の1で寛解を達成します.
- 放射性ヨウ素療法は,第一線治療としてますます使用され,再発したグレイス型甲状腺機能向上症に好ましい.
- トータル甲状腺切除術は,一部の患者にとって有効な選択肢です.
結論:
- 甲状腺毒性症の現在の治療法は,特にグレイヴス病の寛解率に関して,限界があります.
- 放射性ヨウ素療法は,特に再発した症例では,重要な治療方法です.
- 将来の研究は,ホルモンの過剰生産を管理するだけでなく,疾患プロセスを調節する新しいアプローチに焦点を当てます.
関連する概念動画
Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
